Vaccines for human papilloma virus and methods for using the same

Patent metadata

Field	Value
Publication number	US-10905755-B2
Application number	US-201916298006-A
Country	US
Kind code	B2
Filing date	Mar 11, 2019
Priority date	Mar 12, 2013
Publication date	Feb 2, 2021
Grant date	Feb 2, 2021

Abstract

Improved anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV39 E6E7 and HPV45 E6E7. Pharmaceutical composition, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed.

First claim

The invention claimed is:

1. A composition comprising at least one nucleic acid molecule comprising a nucleotide sequence encoding an HPV52 E6-E7 fusion antigen; wherein the nucleotide sequence is selected from the group consisting of:
a nucleotide sequence that encodes SEQ ID NO:20, a nucleotide sequence that is at least 98% homologous to a nucleotide sequence that encodes SEQ ID NO:20, and a nucleotide sequence that encodes a fragment of SEQ ID NO:20;
wherein the fragment of SEQ ID NO:20 comprises 60% or more of the full length of SEQ ID NO:20.

2. The composition of claim 1 , further comprising at least one nucleotide sequence encoding an HPV E6-E7 fusion antigen selected from the group consisting of:
nucleotide sequence that encodes SEQ ID NO:2; nucleotide sequence that encodes SEQ ID NO:4; nucleotide sequence that encodes SEQ ID NO:6; nucleotide sequence that encodes SEQ ID NO:8; nucleotide sequence that encodes SEQ ID NO:18; nucleotide sequence that encodes SEQ ID NO:22; nucleotide sequence that encodes SEQ ID NO:24; nucleotide sequence that encodes SEQ ID NO:25; nucleotide sequence that encodes SEQ ID NO:26;
a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes SEQ ID NO:2; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes SEQ ID NO:4; nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes SEQ ID NO:6; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes SEQ ID NO:8; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes SEQ ID NO:18; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes SEQ ID NO:22; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes SEQ ID NO:24; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes SEQ ID NO:25; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes SEQ ID NO:26;
a nucleotide sequence that encodes a fragment of SEQ ID NO:2; a nucleotide sequence that encodes a fragment of SEQ ID NO:4; a nucleotide sequence that encodes a fragment of SEQ ID NO:6; a nucleotide sequence that encodes a fragment of SEQ ID NO:8; a nucleotide sequence that encodes a fragment of SEQ ID NO:18; a nucleotide sequence that encodes a fragment of SEQ ID NO:22; a nucleotide sequence that encodes a fragment of SEQ ID NO:24; a nucleotide sequence that encodes a fragment of SEQ ID NO:25; a nucleotide sequence that encodes a fragment of SEQ ID NO:26;
a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes a fragment of SEQ ID NO:2; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes a fragment of SEQ ID NO:4; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes a fragment of SEQ ID NO:6; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes a fragment of SEQ ID NO:8; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes a fragment of SEQ ID NO:18; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes a fragment of SEQ ID NO:22; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes a fragment of SEQ ID NO:24; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes a fragment of SEQ ID NO:25; and a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes a fragment of SEQ ID NO:26.

3. The composition of claim 1 , comprising one or more nucleotide sequences selected from the group consisting of:
SEQ ID NO:19; a nucleotide sequence that is at least 95% homologous to SEQ ID NO:19; and a fragment of SEQ ID NO:19.

4. The composition of claim 2 , wherein at least one nucleotide sequence encoding at least one HPV E6-E7 fusion antigen is selected from the group consisting of:
nucleotide sequence that encodes SEQ ID NO:2; nucleotide sequence that encodes SEQ ID NO:4; nucleotide sequence that encodes SEQ ID NO:6; nucleotide sequence that encodes SEQ ID NO:8; nucleotide sequence that encodes SEQ ID NO:18; nucleotide sequence that encodes SEQ ID NO:22; nucleotide sequence that encodes SEQ ID NO:24;
a nucleotide sequence that is at least 95% homologous to a nucleotide sequence nucleotide sequence that encodes SEQ ID NO:2; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes SEQ ID NO:4; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes SEQ ID NO:6; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes SEQ ID NO:8; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes SEQ ID NO:18; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes SEQ ID NO:22; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes SEQ ID NO:24;
a nucleotide sequence that encodes a fragment of SEQ ID NO:2 a nucleotide sequence that encodes a fragment of SEQ ID NO:4; a nucleotide sequence that encodes a fragment of SEQ ID NO:6; a nucleotide sequence that encodes a fragment of SEQ ID NO:8; a nucleotide sequence that encodes a fragment of SEQ ID NO:18; a nucleotide sequence that encodes a fragment of SEQ ID NO:22; a nucleotide sequence that encodes a fragment of SEQ ID NO:24;
a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes a fragment of SEQ ID NO:2; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes a fragment of SEQ ID NO:4; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes a fragment of SEQ ID NO:6; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes a fragment of SEQ ID NO:8; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes a fragment of SEQ ID NO:18; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes a fragment of SEQ ID NO:22; and a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes a fragment of SEQ ID NO:24.

5. The composition of claim 2 , wherein at least one nucleotide sequence encoding at least one HPV E6-E7 fusion antigen is selected from the group consisting of:
nucleotide sequence that encodes SEQ ID NO:6; nucleotide sequence that encodes SEQ ID NO:8; nucleotide sequence that encodes SEQ ID NO:18; nucleotide sequence that encodes SEQ ID NO:22; nucleotide sequence that encodes SEQ ID NO:24;
a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes SEQ ID NO:6; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes SEQ ID NO:8; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes SEQ ID NO:18; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes SEQ ID NO:22; a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes SEQ ID NO:24;
a nucleotide sequence that encodes a fragment of SEQ ID NO:6; a nucleotide sequence that encodes a fragment of SEQ ID NO:8; a nucleotide sequence that encodes a fragment of SEQ ID NO:18; a nucleotide sequence that encodes a fragment of SEQ ID NO:22; a nucleotide sequence that encodes a fragment of SEQ ID NO:24;
a nucleotide sequence that is at least 95% homologous to a nucleotide sequence that encodes a fragment of SEQ ID NO:6; a nucleotide sequence that is at least

Assignees

• Univ Pennsylvania
• Inovio Pharmaceuticals Inc

Inventors

• Weiner David
• Yan Jian

Classifications

• C12N2710/20034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2710/20022

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C07K14/005

  from viruses · CPC title

• A61P31/20

  for DNA viruses · CPC title

• A61K2039/54

  characterised by the route of administration · CPC title